You are here

EVRYS BIO LLC

Company Information
Address
3805 OLD EASTON RD
DOYLESTOWN, PA 18902-8400
United States



Information

UEI: TM98GAF3Z6Q6

# of Employees: 8


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: Yes



Award Charts




Award Listing

  1. A single antiviral to treat multiple opportunistic infections

    Amount: $999,998.00

    PROJECT SUMMARY/ABSTRACT Immunosuppressed transplant patients have heightened susceptibility to environmental pathogens as well as adventitious agents traveling with donor tissues or resident in the r ...

    SBIRPhase II2023Department of Health and Human Services National Institutes of Health
  2. Development of a host-targeted antiviral as a chronic hepatitis B therapeutic with potential to achieve a functional cure

    Amount: $300,000.00

    FAST-TRACK PHASE I and II ABSTRACT Without treatment, chronic hepatitis B virus (HBV) infection can lead to cirrhosis of the liver, hepatocellular carcinoma or liver failure. Current therapies effecti ...

    SBIRPhase I2021Department of Health and Human Services National Institutes of Health
  3. A single antiviral to treat multiple opportunistic infections

    Amount: $3,901,084.00

    Current standard-of-care antiviral regimens rely on direct-acting antivirals (DAAs) possessing inherent liabilities. DAAs are generally active against only one virus or a closely related, family of vi ...

    SBIRPhase II2019Department of Health and Human Services National Institutes of Health
  4. SIRTUIN AGONISTS AS PAN INFLUENZA ANTIVIRALS

    Amount: $2,000,000.00

    DESCRIPTIONprovided by applicantCurrent antivirals for influenza infection target specific viral proteinsDue to marked genetic diversitydifferent strains of influenza demonstrate differential sensitiv ...

    SBIRPhase II2018Department of Health and Human Services National Institutes of Health
  5. Host-Targeted Antiviral Drugs Providing Rapid, Scalable, Stable, Broad-Spectrum MedicalCountermeasure Against Marburg Virus

    Amount: $149,997.48

    In a pandemic or exposure to weaponized Marburg virus the morbidity, mortality and social unrest that will ensue before vaccines orMilitary operating on foreign soil as well as to the population of th ...

    STTRPhase I2018Department of Defense Office for Chemical and Biological Defense
  6. SIRTUIN AGONISTS AS PAN INFLUENZA ANTIVIRALS

    Amount: $304,858.00

    DESCRIPTION provided by applicant Current antivirals for influenza infection target specific viral proteins Due to marked genetic diversity different strains of influenza demonstrate differential ...

    SBIRPhase I2016Department of Health and Human Services National Institutes of Health
  7. An Antiviral to Treat Progressive Multifocal Leukoencephalopathy_(PML)

    Amount: $224,999.00

    DESCRIPTION provided by applicant Reactivation of polyomavirus JCV in the brains of immunosuppressed individuals causes a devastating disease called progressive multifocal leukoencephalopathy PML ...

    SBIRPhase I2015Department of Health and Human Services National Institutes of Health
  8. Host-Targeted Mechanism of Action for Treatment of Seasonal and Pandemic Influenz

    Amount: $225,000.00

    DESCRIPTION (provided by applicant): Despite improvements in vaccine design, manufacture, and distribution, influenza A infection remains a significant public health concern. The February 2013 CDC In ...

    SBIRPhase I2014Department of Health and Human Services National Institutes of Health
  9. A Single Antiviral to Treat Multiple Opportunistic Infections

    Amount: $224,999.00

    DESCRIPTION (provided by applicant): Transplant patients are quite susceptible to opportunistic viral infection resulting from immune suppression necessary for maintenance of their graft. In the case ...

    SBIRPhase I2014Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government